These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 20642374

  • 1. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D, Basaria S.
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [Abstract] [Full Text] [Related]

  • 2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ.
    J Androl; 1998 Aug; 19(6):761-8. PubMed ID: 9876028
    [Abstract] [Full Text] [Related]

  • 3. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
    Dinsmore WW, Wyllie MG.
    BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C, Harnett M, Dobs AS, Swerdloff RS.
    J Androl; 2010 Jul; 31(5):457-65. PubMed ID: 20133964
    [Abstract] [Full Text] [Related]

  • 5. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M.
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [Abstract] [Full Text] [Related]

  • 6. A new testosterone gel (fortesta) for hypogonadism.
    Med Lett Drugs Ther; 2011 Apr 18; 53(1362):29-30. PubMed ID: 21502933
    [Abstract] [Full Text] [Related]

  • 7. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA, Triggiani V, Carbone MD, Corona G, Tafaro E, Licchelli B, Guastamacchia E.
    J Sex Med; 2011 Dec 18; 8(12):3471-8. PubMed ID: 21995803
    [Abstract] [Full Text] [Related]

  • 8. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men.
    Fennell C, Sartorius G, Ly LP, Turner L, Liu PY, Conway AJ, Handelsman DJ.
    Clin Endocrinol (Oxf); 2010 Jul 18; 73(1):102-9. PubMed ID: 19891698
    [Abstract] [Full Text] [Related]

  • 9. Testosterone supplementation: what and how to give.
    Jockenhövel F.
    Aging Male; 2003 Sep 18; 6(3):200-6. PubMed ID: 14628500
    [Abstract] [Full Text] [Related]

  • 10. Recent trends in the treatment of testosterone deficiency syndrome.
    Hong BS, Ahn TY.
    Int J Urol; 2007 Nov 18; 14(11):981-5. PubMed ID: 17956520
    [Abstract] [Full Text] [Related]

  • 11. Testosterone metabolism and replacement therapy in patients with end-stage renal disease.
    Johansen KL.
    Semin Dial; 2004 Nov 18; 17(3):202-8. PubMed ID: 15144546
    [Abstract] [Full Text] [Related]

  • 12. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG, Park MG, Lee SW, Park K, Park JK, Kim SW, Park NC, Ahn TY, Paick JS, Seo JT, Yang DY, Lee JY, Kim JJ.
    J Sex Med; 2010 Jun 18; 7(6):2253-2260. PubMed ID: 20345732
    [Abstract] [Full Text] [Related]

  • 13. Testosterone treatment comes of age: new options for hypogonadal men.
    Nieschlag E.
    Clin Endocrinol (Oxf); 2006 Sep 18; 65(3):275-81. PubMed ID: 16918944
    [Abstract] [Full Text] [Related]

  • 14. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Clin Endocrinol Metab; 2004 Nov 18; 89(11):5429-34. PubMed ID: 15531493
    [Abstract] [Full Text] [Related]

  • 15. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, Saghir A, Blast Study Group.
    Int J Clin Pract; 2014 Feb 18; 68(2):203-15. PubMed ID: 24355040
    [Abstract] [Full Text] [Related]

  • 16. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S, Nieschlag E.
    J Androl; 2002 Feb 18; 23(3):419-25. PubMed ID: 12002444
    [Abstract] [Full Text] [Related]

  • 17. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T, Schubert M, Freude S, Hübler D, Gouni-Berthold I, Schumann C, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Endocrinol Invest; 2008 Aug 18; 31(8):718-23. PubMed ID: 18852533
    [Abstract] [Full Text] [Related]

  • 18. Hypogonadal men treated with oral testosterone undecanoate.
    Sarris S, Swyer GI, Lawrence DM.
    Acta Eur Fertil; 1977 Dec 18; 8(4):297-9. PubMed ID: 610314
    [Abstract] [Full Text] [Related]

  • 19. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
    Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren L, Nieschlag E.
    Asian J Androl; 2007 May 18; 9(3):291-7. PubMed ID: 17486268
    [Abstract] [Full Text] [Related]

  • 20. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
    Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A.
    Urology; 2014 Jan 18; 83(1):167-73. PubMed ID: 24139347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.